BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 16004813)

  • 41. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
    Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
    Burkes RL; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Jones D; Farooq S; McGlaughlin J; Ginsberg RJ
    Lung Cancer; 2005 Jan; 47(1):103-9. PubMed ID: 15603860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Our experience with patients operated after neoadjuvant therapy].
    Juhász M; Egri G; Váradi C; Mészáros Z; Keszler P
    Magy Seb; 2004 Dec; 57(6):332-5. PubMed ID: 15803876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
    Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
    Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Multimodal treatment of non small cell lung cancer].
    Stoelben E; Digel W; Henke M; Passlick B
    Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications.
    Cerfolio RJ; Talati A; Bryant AS
    Ann Thorac Surg; 2009 Sep; 88(3):930-5; discussion 935-6. PubMed ID: 19699923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
    Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K;
    J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study].
    Xu G; Rong T; Lin P
    Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):228-30. PubMed ID: 10921016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pneumonectomy after chemotherapy: morbidity, mortality, and long-term outcome.
    Alifano M; Boudaya MS; Salvi M; Collet JY; Dinu C; Camilleri-Broët S; Régnard JF
    Ann Thorac Surg; 2008 Jun; 85(6):1866-72; discussion 1872-3. PubMed ID: 18498785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
    Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
    Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.